Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) – Equities researchers at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Armata Pharmaceuticals in a note issued to investors on Wednesday, August 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.47). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2024 earnings at ($0.29) EPS and FY2024 earnings at ($1.02) EPS.
Armata Pharmaceuticals Stock Performance
NYSEAMERICAN ARMP opened at $2.27 on Friday. Armata Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $4.48. The stock has a market capitalization of $82.13 million, a PE ratio of -1.00 and a beta of 0.76.
Hedge Funds Weigh In On Armata Pharmaceuticals
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Read More
- Five stocks we like better than Armata Pharmaceuticals
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 8/12 – 8/16
- What are earnings reports?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.